Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
This article was originally published in PharmAsia News
PERTH, Australia - As part of the new federal budget announced May 11, Medicines Australia has negotiated price-saving measures with the Australian government that will cut prices on off-patent medicines in exchange for an assurance from the government that innovative prices on drugs will not be cut for four years
You may also be interested in...
A new government in Australia faces a budget gap that will soon bring health care reimbursement with industry focused on a pledge by the Liberal Party to restore the independence of the Pharmaceutical Benefits Advisory Committee.
Australia’s Federal Election is on Sept. 7, and both Medicines Australia and AusBiotech have been lobbying the Labor and the Liberal National parties to see what the incoming government can offer the pharmaceutical, medical device and biotechnology industries.
Industry group Medicines Australia attempts to refute a study that says the payment structure of the Pharmaceutical Benefits Scheme is approaching an unsustainable level.